Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened

Key Points

• Immatics shares saw unusually heavy trading volume, with about 1.01 million shares changing hands—122% above the prior session—while the stock traded near $8.94.
• Analyst sentiment remains mixed but leans positive: six analysts rate the stock Buy, one rates it Hold and one Sell, producing a Moderate Buy consensus and an average price target of $20.80.
• The clinical-stage biotechnology company reported a quarterly loss of $0.50 per share, missing expectations by $0.08, while revenue of $8.81 million also fell short of estimates; institutional investors and hedge funds own 64.41% of the stock.

Shares of Immatics N.V. (NASDAQ:IMTX - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 1,005,292 shares changed hands during trading, an increase of 122% from the previous session's volume of 452,098 shares.The stock last traded at $8.94 and had previously closed at $8.99.

Analysts Set New Price Targets

IMTX has been the topic of a number of analyst reports. TD Cowen began coverage on shares of Immatics in a research report on Tuesday, April 28th. They set a "buy" rating on the stock. Chardan Capital reiterated a "buy" rating and issued a $25.00 price target on shares of Immatics in a research note on Tuesday, May 19th. Wall Street Zen lowered Immatics from a "hold" rating to a "sell" rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings downgraded Immatics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Immatics presently has an average rating of "Moderate Buy" and an average target price of $20.80.

Immatics Trading Up 1.6%

The company has a 50 day moving average price of $9.84 and a 200-day moving average price of $10.09. The company has a market cap of $1.22 billion, a P/E ratio of -4.62 and a beta of 1.32.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.08). The business had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. Equities analysts expect that Immatics N.V. will post -1.67 earnings per share for the current year.

Hedge Funds Weigh In On Immatics

A number of institutional investors have recently added to or reduced their stakes in IMTX. Vanguard Personalized Indexing Management LLC boosted its position in Immatics by 3.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company's stock valued at $518,000 after buying an additional 1,739 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company's stock valued at $25,000 after acquiring an additional 2,231 shares in the last quarter. Barclays PLC grew its position in Immatics by 11.4% during the 4th quarter. Barclays PLC now owns 28,185 shares of the company's stock worth $296,000 after acquiring an additional 2,874 shares during the last quarter. Virtus Investment Advisers LLC increased its holdings in Immatics by 43.0% in the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company's stock worth $278,000 after purchasing an additional 7,965 shares in the last quarter. Finally, Quarry LP bought a new position in Immatics in the fourth quarter valued at about $84,000. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Company Profile

Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.